-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Nine Years Without a New FDA Approved Therapy for Myelodysplastic Syndromes: How Can We Break Through the Impasse?

Program: Education Program
Session: Myelodysplastic Syndromes: Evolving Diagnosis and Therapy
Saturday, December 5, 2015, 9:30 AM-11:00 AM
Valencia D (W415D), Level 4 (Orange County Convention Center)
Sunday, December 6, 2015, 7:30 AM-9:00 AM
Valencia D (W415D), Level 4 (Orange County Convention Center)

Amy E. DeZern, MD, MHS

The Johns Hopkins School of Medicine, Baltimore, MD

Disclosures: No relevant conflicts of interest to declare.

See more of: Myelodysplastic Syndromes: Evolving Diagnosis and Therapy
See more of: Education Program
<< Previous Presentation | Next Presentation